search button

Nedaplatin‑ versus cisplatin‑based chemotherapy in the survival time of patients with non‑small cell lung cancer

  • Authors:
    • Jinlu Shan
    • Yanli Xiong
    • Dong Wang
    • Mingfang Xu
    • Yi Yang
    • Kan Gong
    • Zhenzhou Yang
    • Ge Wang
    • Xueqin Yang

  • View Affiliations

  • Published online on: February 6, 2015     https://doi.org/10.3892/mco.2015.504
  • Pages: 543-549
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nedaplatin (NDP) has been extensively used to treat patients with non‑small cell lung cancer (NSCLC) in the last decade. The present study compared the survival benefits of NDP and cisplatin (DDP) in the treatment of NSCLC. Patients (n=392) with NSCLC were treated with at least two cycles of platinum‑based chemotherapy. Among these patients, 202 received DDP‑based chemotherapy, and 190 received NDP‑based chemotherapy. The overall survival time of the two groups and the toxicity of drugs were analyzed. The results showed that only the chemotherapy cycle duration was found to be statistically different between DDP and NDP groups in all the characteristics. The mean chemotherapy duration was 3.3 cycles in the DDP group, and 4.1 cycles in the NDP group (χ2=20.206, P<0.001). Additionally, the chemotherapy cycle number was also an independent predictive factor for the overall survival time in the multivariate analysis (HR=0.539, P<0.001). The median survival time (MST) was 15 months in the DDP group, and 20 months in the NDP group (χ2=5.189, P=0.023). The 1‑, 2‑ and 3‑year overall survival rates were 62.4, 25.7 and 15.8%, and 78.9, 38.9, and 16.8% in the DPP and NDP groups, respectively. The incidence of grade 3‑4 nausea/vomiting, anorexia and weight loss was higher in the DDP compared to the NDP group (36.1 vs. 8.4%, 17.3 vs. 5.8%, and 9.9 vs. 1%, respectively). In conclusion, NDP‑based chemotherapy had a survival benefit compared to DDP‑based chemotherapy for NSCLC patients, due to the lower toxicity of NDP, which renders this drug more tolerable, thus allowing patients to undergo more cycles of chemotherapy.
View Figures
View References

Related Articles

Journal Cover

May-2015
Volume 3 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Shan J, Xiong Y, Wang D, Xu M, Yang Y, Gong K, Yang Z, Wang G and Yang X: Nedaplatin‑ versus cisplatin‑based chemotherapy in the survival time of patients with non‑small cell lung cancer. Mol Clin Oncol 3: 543-549, 2015
APA
Shan, J., Xiong, Y., Wang, D., Xu, M., Yang, Y., Gong, K. ... Yang, X. (2015). Nedaplatin‑ versus cisplatin‑based chemotherapy in the survival time of patients with non‑small cell lung cancer. Molecular and Clinical Oncology, 3, 543-549. https://doi.org/10.3892/mco.2015.504
MLA
Shan, J., Xiong, Y., Wang, D., Xu, M., Yang, Y., Gong, K., Yang, Z., Wang, G., Yang, X."Nedaplatin‑ versus cisplatin‑based chemotherapy in the survival time of patients with non‑small cell lung cancer". Molecular and Clinical Oncology 3.3 (2015): 543-549.
Chicago
Shan, J., Xiong, Y., Wang, D., Xu, M., Yang, Y., Gong, K., Yang, Z., Wang, G., Yang, X."Nedaplatin‑ versus cisplatin‑based chemotherapy in the survival time of patients with non‑small cell lung cancer". Molecular and Clinical Oncology 3, no. 3 (2015): 543-549. https://doi.org/10.3892/mco.2015.504